Moneycontrol PRO
HomeNewsPfizer

Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

Jump to
  • Buy or sell: Top stock trading ideas by market experts which are good short term bets

    Hadrien Mendonca of IIFL suggests buying SBI with a target Rs 315.

  • Buy Pfizer, target Rs 2,855: Angel Broking

    Buy Pfizer, target Rs 2,855: Angel Broking

    We recommend buying this stock at current levels for a target of Rs 2,855 over the next one month, and a stop loss should be fixed at Rs 2,405.

  • Top 10 expert moneymaking ideas for the short term

    Top 10 expert moneymaking ideas for the short term

    Investors are advised to remain cautious and watch out for two levels: 10,770 on the upside and 10,550 on the down.

  • Profit booking likely on D-St; Top 3 stocks which could give over 10% return

    Profit booking likely on D-St; Top 3 stocks which could give over 10% return

    At this juncture, markets are clearly experiencing their corrective phases (price wise as well as time-wise) and hence, one should not venture into it aggressively.

  • Buy or sell: Top stock trading ideas by market experts which are good short term bets

    Buy or sell: Top stock trading ideas by market experts which are good short term bets

    Mitessh Thakkar of mitesshthakkar.com recommends buying Bajaj Finance with a stop loss of Rs 2099 and target of Rs 2160 and Indian Oil Corporation with a stop loss of Rs 166 and target of Rs 180.

  • Podcast | These 3 stocks may offer 17-19% returns in 6 months

    Podcast | These 3 stocks may offer 17-19% returns in 6 months

    We expect the Nifty to form a higher base by consolidating in a broader range of 10,400–10,850 that would pave the way for the next leg of the upmove.

  • Buy Pfizer, target Rs 2800: Ashish Chaturmohta

    Buy Pfizer, target Rs 2800: Ashish Chaturmohta

    "The stock can be bought at current level and on dips to Rs 2,400 with a stop loss below Rs 2,350 and target of Rs 2,800 levels," says Ashish Chaturmohta of Sanctum Wealth Management.

  • 5 stocks that could deliver 10-18% returns in June series

    5 stocks that could deliver 10-18% returns in June series

    "The immediate resistance for the Nifty is placed at 10,735. If the index crosses above this level then the next target is seen at 10,800-10830," says Ashish Chaturmohta of Sanctum Wealth Management.

  • If you have a 6-month time frame, these 3 stocks could give up to 20-24% return

    If you have a 6-month time frame, these 3 stocks could give up to 20-24% return

    "We expect the Nifty to consolidate within a broader range of 10,300–10,600 amid stock specific action as we are going through the Q4 earnings season," says Dharmesh Shah of ICICI Direct.com.

  • Buy Pfizer, major support in Rs 2,150-2,200 range: Dharmesh Shah

    Buy Pfizer, major support in Rs 2,150-2,200 range: Dharmesh Shah

    The stock has major support in the range of Rs 2,150-2,200 being the confluence of 80% retracement of the previous up move from Rs 2,050 to Rs 2,549 and 12 months EMA, says Dharmesh Shah of ICICI Direct.com Research.

  • Podcast | Nifty likely to consolidate in a 250-point range; buy these 3 stocks for returns up to 21%

    Podcast | Nifty likely to consolidate in a 250-point range; buy these 3 stocks for returns up to 21%

    Here is a list of top three stocks that could deliver up to 21% return in the next six months.

  • Buy or sell: Top stock picks by Dharmesh Shah, Prakash Gaba for May 17

    Buy or sell: Top stock picks by Dharmesh Shah, Prakash Gaba for May 17

    Dharmesh Shah of ICICI Direct.com Research is of the view that one may buy Pfizer with a target of Rs 2960.

  • Divi's Labs, Pfizer among top 5 stocks that could deliver up to 16% return

    Divi's Labs, Pfizer among top 5 stocks that could deliver up to 16% return

    Divis Laboratories, Crompton Greaves Consumer Electricals, Indian Hotels, Pfizer and Bombay Dyeing could give up to 16% return in the short term

  • Top five stocks to buy on Wednesday which could give up to 15% return in short term

    Top five stocks to buy on Wednesday which could give up to 15% return in short term

    Broadly post the recent fall in the market, the index is likely to trade in a range of 10,740-10,400 and consolidate around these levels.

  • Bull's Eye: Buy Thermax, LT Foods, JK Paper, Pfizer, Natco Pharma, GHCL

    Bull's Eye: Buy Thermax, LT Foods, JK Paper, Pfizer, Natco Pharma, GHCL

    Ruchit Jain of Angel Broking is of the view that one may buy NIIT Technologies with a target of Rs 681.

  • Fund managers are not gung-ho on these 20 stocks; do you have them in your portfolio?

    Fund managers are not gung-ho on these 20 stocks; do you have them in your portfolio?

    Rising liquidity in domestic MFs is one of the biggest factors in driving rally on D-Street which is trading at record highs.

  • Prefer Aurobindo Pharma, says Gaurang Shah

    Prefer Aurobindo Pharma, says Gaurang Shah

    Gaurang Shah of Geojit BNP Paribas is of the view that one may prefer Aurobindo Pharma.

  • Tulsian's take on ICICI Pru Life listing, MRF & other tyre shrs

    Tulsian's take on ICICI Pru Life listing, MRF & other tyre shrs

    SP Tulsian of sptulsian.com tells CNBC-TV18 why he would not give a buy call on MRF stock which touched Rs 50,000-mark in trade Wednesday. He also shares his take on other tyre stocks.

  • Stay invested in Pfizer, says Shahina Mukadam

    Stay invested in Pfizer, says Shahina Mukadam

    Shahina Mukadam, Independent Market Expert advises holding Pfizer.

  • Here are top 10 stocks to keep an eye on March 15

    Here are top 10 stocks to keep an eye on March 15

    CNBC-TV18's analysts give you stocks to keep on your radar for trade today: The stocks that are likely to be under pressure are Lupin, Chambal Fertiliser, Tree House Education, United Breweries and Bajaj Auto while the stocks that are likely to gain are Wipro, Pfizer, Spicejet, Eveready, Indian Hume, Tata Motors and Tech Mahindra.

  • Century Textiles positional short; buy Lakshmi Machine: Sukhani

    Century Textiles positional short; buy Lakshmi Machine: Sukhani

    According to Sudarshan Sukhani of s2analytics.com, Century Textiles is a positional short and recommends buying Lakshmi Machine Works.

  • Vivimed Labs may test Rs 500 in 6 months, says SP Tulsian

    Vivimed Labs may test Rs 500 in 6 months, says SP Tulsian

    SP Tulsian of sptulsian.com is of the view that Vivimed Labs may test Rs 500 in next six months.

  • Buy Pfizer, advises Sudarshan Sukhani

    Buy Pfizer, advises Sudarshan Sukhani

    Sudarshan Sukhani of s2analytics.com recommends buying Pfizer.

  • Check out: Top 10 stocks of the day

    Check out: Top 10 stocks of the day

    Here's a list of top 10 stocks that are in news today due to fourth quarter earnings, entry into F&O segment and merger deals.

  • Hold Pfizer, says Vishal Malkan

    Hold Pfizer, says Vishal Malkan

    Vishal Malkan of malkansview.com is of the view that one can hold Pfizer for long term.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347